文献速递肾癌与肾肿瘤

部分肾切除术与经皮消融治疗肾细胞癌的长期结局:倾向性匹配分析

Long-term Outcomes of Partial Nephrectomy Versus Percutaneous Ablation for Renal Cell Carcinoma: A Propensity-Matched Analysis.
PubMed 文献 · Urology · 2025-08-05

本研究基于TriNetX多机构数据库的回顾性队列,纳入9374例部分肾切除术、2169例冷冻消融和1003例热消融的肾细胞癌患者,经倾向性评分匹配后比较围手术期结局和10年生存、转移风险及再干预率。结果示消融组围手术期并发症更少,但10年再干预率更高,而10年生存率相似。

要点

  • 部分肾切除术围手术期并发症更高,但10年再干预率显著低于消融。
  • 消融组10年再干预率:冷冻消融13.0%,热消融9.6%,部分肾切除1.3%。
  • 三组10年生存率相似(89.4% vs 89.2% vs 87.8%,P>.05)。

核心结论

  • 部分肾切除术与经皮消融治疗肾细胞癌的10年生存率和转移率相当。
  • 消融围手术期并发症更低,但10年再干预率更高。

研究设计与样本

  • 回顾性队列研究,使用TriNetX多机构去标识电子病历数据库。
  • 纳入2004-2025年接受部分肾切除术、冷冻消融或热消融的成人肾细胞癌患者。
  • 采用倾向性评分匹配平衡年龄、合并症、肾功能和BMI。
  • 样本量:部分肾切除术9374例,冷冻消融2169例,热消融1003例。

主要发现

  • 部分肾切除术住院时间更长(1.2天 vs 冷冻消融0.4天和热消融0.3天;P<.01)。
  • 部分肾切除术ICU入住率更高(4.0% vs 1.4%和1.0%;P<.01)。
  • 部分肾切除术输血率更高(4.3% vs 1.4%和0.9%;P<.01)。
  • 10年再干预率:冷冻消融13.0%,热消融9.6%,部分肾切除术1.3%(P<.01)。
  • 10年生存率:部分肾切除术89.4%,冷冻消融89.2%,热消融87.8%(P>.05)。

临床怎么用

  • 治疗选择应个体化,综合考虑合并症和手术风险。
  • 对于高手术风险患者,消融可降低围手术期并发症,但需告知再干预风险较高。

局限性

  • 回顾性研究设计。
  • 使用去标识数据库,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare peri-procedural outcomes and long-term (10-year) survival, metastasis risk, and reintervention rates between partial nephrectomy versus image-guided ablation (cryoablation and heat-based ablation) for renal cell carcinoma (RCC). MATERIALS AND METHODS: This Institutional Review Board-approved, retrospective cohort study utilized TriNetX (TriNetX LLC, Cambridge, MA), a multi-institution database of deidentified electronic medical records. Adult patients with RCC who underwent partial nephrectomy, cryoablation, or heat-based thermal ablation 2004-2025 were identified. Propensity score matching (PSM) was used to balance cohorts for age, comorbidities, renal function, and BMI. Outcomes included post-procedural complications, hospital stay, need for additional renal interventions, survival, and treatment of metastatic disease. Statistical analyses included Kaplan-Meier survival curves and chi-square tests for categorical variables. RESULTS: A total of 9374 partial nephrectomy, 2169 cryoablation, and 1003 heat-based ablation patients were included. After PSM, partial nephrectomy was associated with longer hospital stays (1.2 vs 0.4 days for cryoablation and 0.3 days for heat-based ablation; P<.01), increased intensive care unit admissions (4.0% vs 1.4% and 1.0%; P<.01), and higher blood transfusion rates (4.3% vs 1.4% and 0.9%; P<.01). However, ablation was associated with increased reintervention rates at 10 years (cryoablation: 13.0%; heat-based ablation: 9.6%) compared to partial nephrectomy (1.3%; P<.01). Ten-year survival rates were similar across groups (partial nephrectomy: 89.4%, cryoablation: 89.2%, heat-based ablation: 87.8%; P>.05). CONCLUSION: Partial nephrectomy and percutaneous ablation demonstrate comparable 10-year survival and metastasis rates for RCC. Ablation confers lower procedural morbidity but higher reintervention rates. Findings support patient-specific treatment selection considering comorbidities and procedural risks.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Stamper M, Collins J, Arellano RS, et al. Long-term Outcomes of Partial Nephrectomy Versus Percutaneous Ablation for Renal Cell Carcinoma: A Propensity-Matched Analysis. Urology. 2025. PMID: 40754018. doi:10.1016/j.urology.2025.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。